


CANCER

Principles & Practice of Oncology



5th Edition

*Vincent T. DeVita, Jr.
Samuel Hellman
Steven A. Rosenberg*


Compliments of

DOCKET
A L A R M

Find authenticated court documents without watermarks at docketalarm.com.

CANCER

Principles & Practice of Oncology



5th Edition



Lippincott - Raven

P U B L I S H E R S

Philadelphia • New York

Project Editor: Grace R. Caputo
Production Manager: Caren Erlichman
Senior Production Coordinator: Kevin P. Johnson
Design Coordinator: Melissa Olson
Indexers: Linda K. Fetters and Alexandra Nickerson
Compositor: Maryland Composition Company
Printer: Rand McNally, Taunton, MA.

5th Edition

Copyright © 1997 by Lippincott–Raven Publishers.

Copyright © 1993, 1989, 1985, 1982 by J.B. Lippincott Company. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means—electronic, mechanical, photocopy, recording, or otherwise—without the prior written permission of the publisher, except for brief quotations embodied in critical articles and reviews. Printed in the United States of America. For information write Lippincott–Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106-3780.

Materials appearing in this book prepared by individuals as part of their official duties as U.S. Government employees are not covered by the above-mentioned copyright.

Library of Congress Cataloging-in-Publication Data

Cancer: principles and practice of oncology/[edited by] Vincent T. DeVita, Jr., Samuel Hellman, Steven A. Rosenberg; 290 contributors.—5th ed.

p. cm.

Includes bibliographical references.

Includes index.

ISBN 0-397-51573-1 (one-vol. ed.)

ISBN 0-397-51574-X (two-vol. set)

ISBN 0-397-51575-8 (vol. 1)

ISBN 0-397-51576-6 (vol. 2)

ISSN 0892-0567

1. Cancer. 2. Oncology. I. DeVita, Vincent T., Jr. II. Hellman, Samuel. III. Rosenberg, Steven A.

Care has been taken to confirm the accuracy of the information presented and to describe generally accepted practices. However, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, express or implied, with respect to the contents of the publication.

The authors, editors, and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

Some drugs and medical devices presented in this publication have Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the health care provider to ascertain the FDA status of each drug or device planned for use in their clinical practice.

9 8 7 6 5 4 3 2 1

Pathology and Biologic Features 2243
 Diagnosis and Staging 2249
 Patterns of Clinical Presentation 2252
 Immunologic Abnormalities 2254
 Treatment 2255
 Hodgkin's Disease in HIV-Positive Patients 2274
 Complications of Therapy 2274
 New Drugs and Biologics in Hodgkin's Disease 2274

45

Leukemias 2285

SECTION 1 Molecular Biology of the Leukemias 2285

ISSA KHOURI
 FELIX GARCIA SANCHEZ
 ALBERT B. DEISSEROTH
 Chronic Myelogenous Leukemia 2285
 Acute Myelogenous Leukemia 2287
 Changes in CML 2289
 Genetic Changes in ALL: Enumerative Chromosomal Abnormalities of
 Leukemic Syndromes 2289
 Chimeric Transcriptional Regulatory Proteins in ALL 2290
 Translocations Resulting in Lineage-Specific Patterns of Transcriptional
 Regulatory Proteins 2290
 Leukemic Syndromes Organized by the Chromosomes Involved 2291
 Application of the Structural Information Derived From the Study
 of Chromosomal Translocations to the Therapy of Leukemia and
 Solid Tumors 2292
 Summary 2292

SECTION 2 Acute Leukemias 2293

DAVID A. SCHEINBERG
 PETER MASLAK
 MARK WEISS
 Epidemiology and Etiology 2293
 Biology of Acute Leukemias 2295
 Diagnosis and Classification of Acute Leukemias 2296
 Principles of Therapy for Acute Leukemia 2300
 Principles of Clinical Management of Acute Leukemia 2303
 Treatment of Newly Diagnosed Acute Myelogenous Leukemia 2304
 Treatment of Relapsed Acute Myelogenous Leukemia 2308
 Acute Promyelocytic Leukemia 2310
 General Principles for the Treatment of Adult Acute Lymphoblastic
 Leukemia 2310
 Prognostic Features in Adult Acute Lymphoblastic Leukemia 2311
 Treatment of Newly Diagnosed Adult Patients With Adult Lymphoblastic
 Leukemia 2312
 Treatment of Relapsed or Refractory Adult Patients With Acute
 Lymphoblastic Leukemia 2313
 Central Nervous System Relapse in Adult Acute Lymphoblastic
 Leukemia 2314
 Bone Marrow Transplant for Adult Acute Lymphoblastic
 Leukemia 2314

Treatment of Mature B-Cell Acute Lymphoblastic Leukemia 2314
Granulocyte Sarcomas, Leukemia Cutis, and Other Extramedullary
Leukemic Involvement 2315
Biological and Immunological Therapies of Acute Leukemias 2315
Conclusion 2316

SECTION 3 *Chronic Leukemias* 2321

ALBERT B. DEISSEROTH
HAGOP KANTARJIAN
MICHAEL ANDREEFF
MOSHE TALPAZ
MICHAEL J. KEATING
ISSA KHOURI
RICHARD B. CHAMPLIN

Chronic Lymphocytic Leukemia 2321
Prolymphocytic Leukemia 2327
Hairy Cell Leukemia 2327
T-Cell Chronic Lymphocytic Leukemia 2328
Chronic Myelogenous Leukemia 2328
Summary 2338

SECTION 4 *Plasma Cell Neoplasms* 2344

SYDNEY E. SALMON
J. ROBERT CASSADY

History 2344
Incidence and Mortality 2346
Pathogenesis 2347
Pathology 2349
Diagnosis and Clinical Staging of Myeloma 2352
Treatment 2355
Complications and Special Problems 2369
Other Plasma Cell Neoplasms 2375
Perspective 2379

SECTION 5 *Myelodysplastic Syndromes* 2388

DAVID A. SCHEINBERG
PETER MASLAK
MARK WEISS

Incidence, Etiology, and Classification 2388
Biology of Myelodysplastic Syndromes 2389
Diagnosis 2389
Prognosis in Myelodysplastic Syndromes 2390
Specific Syndromes of Myelodysplastic Syndromes 2391
Chronic Myelomonocytic Leukemia 2391
Treatment of Myelodysplastic Syndromes 2391
Hematopoietic Growth Factors 2392
Drug Therapy of Myelodysplastic Syndromes Including
Chemotherapy 2393
Allogeneic Bone Marrow Transplantation for Myelodysplastic
Syndromes 2394

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.